tbuckley/cabot-search huggingface dataset:
Treatment of SCLC: Consensus Needed
Authors: F. S. Antoine
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Treatment of SCLC: Consensus Needed Get access Florence S. Antoine Florence S. Antoine Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 24, 20 December 1989, Pages 1856–1858, https://doi.org/10.1093/jnci/81.24.1856 Published: 20 December 1989
Reply to Dr. Tursi
Authors: P. van Putten, F. ter Borg, R. Adang, J. Koornstra, M. Romberg-Camps, R. Timmer, A. Poen, E. Kuipers, M. van Leerdam
Journal: Endoscopy (2013)

We appreciate the comments raised by Dr. Tursi. Medicolegal issues are indeed important in any field of medicine, including endoscopy. Growing health care demands and costs in all Western countries require unprecedented solutions, including selective use of resources and rescheduling of tasks. The latter includes rescheduling of tasks from registered nurses to other personnel, as well as rescheduling tasks from physicians to specialized nurses. We fully agree that this can only be done under strict legal authorization. To accomplish this, one first needs evidence that nurses can perform a task competently, adequately, and safely; hence our research as presented in Endoscopy [1]. The next step is to search for legal possibilities. In the Netherlands, for example, rules for health care professionals are set by the Individual Health Care Professionals Act (Wet BIG). This act authorizes nurses to be trained in and perform specific delegated tasks, provided the tasks are performed in accordance with the quality standards and under a prespecified level of supervision. Nurses trained and assessed to be competent to perform a specific procedure will be judged accordingly, and are personally responsible for the procedure, including its complications. Medical liability insurance for hospitals and professionals covers medical malpractice costs. However, it is the responsibility of local institutions to define these rules and responsibilities to clarify the medicolegal implications.
Abstract 4933: Sanger sequencing of low amount of genomic DNA and FFPE DNA with PCR primers derived from the Ion AmpliSeq cancer hotspot panel
Authors: Edgar H. Schreiber, Adam Broomer, Mark Andersen, Kamini Varma
Journal: Cancer Research (2015)

Abstract The introduction of defined Ion AmpliSeq™ panels for detection and characterization of actionable mutations occurring in tumor tissue has the potential to revolutionize translational oncology research. The Ion Ampliseq™ cancer hotspot panel version 2 (CHP v2) by Ion Torrent includes 207 actionable mutation targets present in 50 genes and the more comprehensive Ion Oncomine™ cancer panel (OCP) contains over 2000 mutations. A hallmark of these Ion Torrent Ampliseq cancer panels is the low amount of input DNA needed which is critical when the clinical specimen material is limited such as with fine needle biopsy or FFPE samples. Typically, 10 ng of DNA obtained from these sources is sufficient to produce informative sequencing data. Often, cancer-causing or promoting mutations are detected at relatively low allele frequencies like 10-20% compared to the major normal allele. Many researchers wish to verify these findings of low frequency mutations by an orthologous method such as traditional dye-fluorescent Sanger sequencing on a capillary electrophoresis (CE) instrument such as the Applied Biosystems 3500 genetic analyzer. To that end, we have developed a workflow that enables the amplification and traditional Sanger sequencing of individual Ion AmpliSeq targets directly from the AmpliSeq library starting material. The method requires a retainer of 1 μl (∼ 5%) of the original AmpliSeq preamplification material. A dilution of this aliquot is used as template source for individualized PCR/sequencing reactions. We show that a random selection of 48 targets from the CHPv2 panel could be successfully amplified and Sanger-sequenced from an Ion Torrent Ampliseq library originally prepared from 10 ng of FFPE DNA. Furthermore, we show the successful Sanger-re-sequencing of all individual 24 targets covering the TP53 exons from the same sample processed and pre-amplified with the OncoMine AmpliSeq panel. Taken together, this method will enable researchers to reflex-test potential mutations of interest from very material-limited specimen using Sanger CE sequencing. Citation Format: Edgar H. Schreiber, Adam Broomer, Mark Andersen, Kamini Varma. Sanger sequencing of low amount of genomic DNA and FFPE DNA with PCR primers derived from the Ion AmpliSeq cancer hotspot panel. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4933. doi:10.1158/1538-7445.AM2015-4933
MS-14 * PATIENTS WITH RECURRENT ATYPICAL MENINGIOMA AFTER UPFRONT SURGICAL RESECTION SALVAGED WITH RADIOSURGERY REQUIRE MORE SALVAGE PROCEDURES THAN PATIENTS SALVAGED WITH CONVENTIONAL RADIATION
Authors: J. Kittel, A. Kumar, A. Zimmerman, N. M. Woody, E. S. Murphy, G. H. Barnett, G. Stevens, P. F. Recinos, J. H. Suh, S. T. Chao
Journal: Neuro-Oncology (2014)

PURPOSE/OBJECTIVES: To determine the optimal salvage radiation treatment for recurrent atypical (WHO grade II) meningiomas after upfront surgery alone. METHODS: 35 patients (1997-2013) were treated at the Cleveland Clinic for histologically confirmed atypical meningiomas with upfront surgery alone and eventually required salvage radiation for recurrence. Patients were treated with either fractionated conventional radiation (RT) or stereotactic radiosurgery (SRS). Patients were grouped into a gross total resection group (GTR) or a subtotal resection group (STR) based on Simpson grade and operative notes. Local failure (LF) was defined as failure at or immediately adjacent to the resection cavity. Univariate analysis and Cox regression modeling was used for statistical analysis. Kaplan-Meier and log rank tests were used for survival analysis. RESULTS: Median age and follow up were 62 years (range 30-77) and 28 mo (range: 10-240), respectively. 23 patients received salvage RT and 12 had SRS. Median total dose for RT and SRS were 5940 cGy (range: 2500 - 6000) and 1400 cGy (range: 1000 - 1800), respectively. 10/23 patients (43.4%) experienced LF in the RT group and 8/12 patients (66.7%) experienced LF in the SRS group. Extent of initial resection (STR vs GTR, p = 0.12), number of pre-salvage radiation surgeries (1 vs 2 + , p = 0.79), and choice of salvage (RT vs SRS, p = 0.96) did not correlate with local relapse-free survival (LRFS). The number of additional salvage procedures after radiation (post-RT salvage) was significantly different (p = 0.02) between the RT (mean: 0.52 ± 1.1) and SRS groups (mean: 1.33 ± 1.3). OS was not significantly different between groups (p = 0.32). CONCLUSION: Patients initially salvaged with SRS were more likely to require additional salvage procedures, suggesting that the entire resection bed is at risk for recurrence and comprehensive radiation may be necessary. SRS can be used to salvage recurrence after salvage RT.
Correlation of P Blood Group, Vesicoureteral Reflux, and Bacterial Attachment in Patients with Recurrent Pyelonephritis
Authors: Helena Lomberg, Lars Å. Hanson, Bo Jacobsson, Ulf Jodal, Hakon Leffler, Catharina Svanborg Edén
Journal: New England Journal of Medicine (1983)

Bacterial attachment to urinary-tract epithelium is important in the pathogenesis of urinary-tract infection. Most pyelonephritogenic Escherichia coli bind specifically to epithelial-cell receptors, which are glycolipids of the globoseries and also antigens in the P blood-group system. Among 36 girls with recurrent pyelonephritis who did not have vesicoureteral reflux, we found that attaching bacteria were common and the P1 blood-group phenotype was present in 97 per cent, as compared with 75 per cent of 84 age-matched children without urinary-tract infection (P less than 0.01). In 32 girls with recurrent pyelonephritis who had reflux, attaching bacteria were rare, and the frequency of the P1 phenotype was not significantly higher than in controls (82 per cent, P greater than 0.05). In the group of patients with the P1 phenotype, 68 per cent of the urinary bacterial isolates from those without reflux, but only 25 per cent of isolates from those with reflux, bound to globotetraosylceramide, as determined by a receptor-coating technique (P less than 0.001). Our data suggest that, in the absence of reflux, the P1 blood group contributes to susceptibility to recurrent pyelonephritis due to bacteria that bind to the glycolipid receptors of the globoseries. In the presence of reflux, uroepithelial attachment does not seem to confer an advantage to bacteria that infect the kidney.
The Influence of Hospital Volume on Survival after Resection for Lung Cancer
Authors: Peter B. Bach, Laura D. Cramer, Deborah Schrag, Robert J. Downey, Sarah E. Gelfand, Colin B. Begg
Journal: New England Journal of Medicine (2001)

Among patients who have undergone high-risk operations for cancer, postoperative mortality rates are often lower at hospitals where more of these procedures are performed. We undertook a population-based study to estimate the extent to which the number of procedures performed at a hospital (hospital volume) is associated with survival after resection for lung cancer.
Reply to S. V. Murugesan, C. B. Babbs
Authors: J. Vracko, K.-L. Wiechel
Journal: Endoscopy (2007)

We appreciate the interest of Drs. Senthil Murugesan and Chris Babbs in our study of acute cholecystitis, published in the August 2006 issue of Endoscopy, that introduced a new indication for early endoscopic sphincterotomy (ES) in elderly patients at high surgical risk who were suffering from acute cholecystitis, We take the opportunity to comment on their letter and to add further explanation.
Stat Bite: Cervical Cancer Survival Rates 1983-1988
Authors: C. M. Frey
Journal: JNCI Journal of the National Cancer Institute (1993)

Stat Bite : Cervical Cancer Survival Rates 1983–1988 Get access Carolin M. Frey, Ph.D. Carolin M. Frey, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 12, 16 June 1993, Pages 945–946, https://doi.org/10.1093/jnci/85.12.945 Published: 16 June 1993
EARLY USE OF THE SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN THE UNITED STATES: A REPORT FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY
Authors: Daniel J. Friedman, Craig Parzynski, Jeptha Curtis, Paul Varosy, Andrea Russo, Jordan Prutkin, Kristen Patton, Ali Mithani, Sana Al-Khatib
Journal: Journal of the American College of Cardiology (2016)
Clinical Benefit of 11C Methionine PET Imaging as a Planning Modality for Radiosurgery of Previously Irradiated Recurrent Brain Metastases
Authors: Toshiya Momose, Tadashi Nariai, Takuya Kawabe, Motoki Inaji, Yoji Tanaka, Shinya Watanabe, Taketoshi Maehara, Keiichi Oda, Kenji Ishii, Kiichi Ishiwata, Masaaki Yamamoto
Journal: Clinical Nuclear Medicine (2014)

Stereotactic radiosurgery with gamma knife (GK-SRS) generally improves the focal control of brain metastases. Yet in cases of focal recurrence at a previous radiation site, MRI is often imperfect in differentiating between active tumor and radiation injury. We have examined whether the use of C methionine (MET) with PET will facilitate this differentiation and improve the outcome of GK-SRS for focally recurrent brain metastases after prior treatment.Eighty-eight patients underwent GK-SRS for postirradiation recurrent brain metastases. Thirty-four patients received radiation in areas manifesting high MET uptake (PET group) in a dose-planning procedure using MET-PET/MRI fusion images. Fifty-four patients referred from other institutes received radiation based on dose planning information obtained from MRI (MRI group).Sex, age, and the ratio of breast cancer differed significantly between the MRI and PET groups. The total irradiation volume was significantly smaller in the PET group, and the minimal irradiation dose was significantly higher. In a multivariable statistical analysis, the use of MET-PET (P = 0.02) was independently associated with prolonged overall survival after treatment, Karnofsky performance status (P = 0.002), the number of lesions (P = 0.03), and patient's sex (P = 0.02). The median survival time was significantly longer in the PET group (18.1 months) than in the MRI group (8.6 months) (P = 0.01).11C methionine-PET/MRI fusion images for dose planning lengthened survival in patients undergoing GK-SRS for focally recurrent brain metastases.
AI-28 * RECURRENT GLIOBLASTOMAS AFTER TREATMENT WITH BEVACIZUMAB
Authors: G. Tabatabai, J. Felsberg, M. Sabel, K. Kaulich, S. Hofer, M. Westphal, M. Weller, G. Reifenberger
Journal: Neuro-Oncology (2014)

Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, has been evaluated in the treatment of patients with primary or recurrent glioblastoma. We aimed to characterize neuropathological and molecular features in recurrent malignant gliomas after failure of Bevacizumab treatment. We evaluated 11 patients with high-grade astrocytomas (10 glioblastomas, 1 anaplastic astrocytomas) before and after Bevacizumab treatment. Clinical records and neuroimaging findings were retrospectively reviewed for each patient. Histological features included morphology, vessel density, cellularity and proliferation. Immunohistochemical studies were performed for selected signaling molecules, including cMET, phosphoAkt, phosphoRPS6K, phosphoMET, phosphoMAPK (ERK1/2), phosphoSTAT3 and phosphor-mTOR. In addition, we performed a gene amplification analysis of cMET. As a reference cohort, primary and recurrent tumors from 22 patients with high-grade astrocytomas (21 glioblastomas, 1 anaplastic astrocytoma) without Bevacizumab treatment were studied. Radiographic recurrence occurred most often at the initial tumor site in both patient groups. Histologically, most recurrences after Bevacizumab treatment showed reduced vessel density and less prominent microvascular proliferation as compared to the corresponding primary tumors. Whereas most investigated signaling molecules showed variable results, expression of cMET protein was upregulated in 6/10 patients following Bevacizumab treatment. In addition one recurrent tumor after Bevacizumab treatment showed MET gene amplification. Based on our data set, a common feature after bevacizumab treatment is altered vascular morphology and upregulation of cMET protein expression. Thus, therapeutic strategies combining VEGF and cMET inhibition may augment clinical efficacy over VEGF inhibition alone in glioblastoma.
P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS
Authors: D. Dieterich, P. Ferenci, I.M. Jacobson, F. Negro, M. Puoti, J.K. Rockstroh, M.P. Manns, K. Arastéh, C. Oliveira, J.-F. Dufour, E. Zehnter, C. Leen, S. Bhagani, J.O. Stern, A.-M. Quinson, J. Scherer, M. Manero, D.M. Jensen
Journal: Journal of Hepatology (2014)
Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone
Authors: Nilay D. Shah, Victor M. Montori, Harlan M. Krumholz, Karen Tu, G. Caleb Alexander, Cynthia A. Jackevicius
Journal: New England Journal of Medicine (2010)

After the diabetes drug rosiglitazone was linked to an increased risk of MI, the FDA issued a boxed warning for the drug. The warning led to decreases in the rate of rosiglitazone use, but some use persisted, and the level of use varied by location.
Abstract 3021: An in vitro investigation of metabolically sensitive epigenetic biomarkers in breast cancer progression
Authors: Natalie E. Simpson, Volodymyr P. Tryndyak, Frederick A. Beland, Igor P. Pogribny
Journal: Cancer Research (2011)

Abstract Cancer cells, including breast cancer cells, display unique alterations in major cellular metabolic pathways; therefore, it is widely believed that a better understanding of molecular cancer cell metabolism may reveal new approaches to aid in the diagnosis, treatment, and prevention of breast cancer. Results from recent in vivo and in vitro studies have demonstrated substantial metabolic differences between non-invasive and invasive breast cancers. Epigenetic marks, including histone post-translational modifications and DNA methylation, are emerging as biomarkers for most of the major human cancers. Additionally, the histone modifying enzymes (HME) (i.e., histone acetyltransferases, deacetylases, methyltransferases, and demethylases) that regulate these epigenetic changes are metabolically sensitive. In light of these considerations, the goal of the current study was to determine if any metabolic differences between non-invasive epithelial and invasive mesenchymal breast cancer cells are associated with the differences in histone modifications identified previously as being biomarkers of breast cancer progression. By comparing gene expression profiles from non-invasive breast cancer cells with an epithelial phenotype (i.e., MCF-7, MDA-MB-361, and T-47D cells) to invasive cells with an aggressive mesenchymal phenotype (i.e., Hs-578T, BT-549, and especially MDA-MB-231 cells), we determined that many metabolically regulated HMEs are differentially expressed in these cancer cells. We further demonstrated reduced acetylation of histone H3 lysine 9/18, reduced acetylation of histone H4 lysine 16/20, and reduced tri-methylation of histone H4 lysine 20 in breast cancer cells with a mesenchymal phenotype as compared to cells with an epithelial phenotype. Interestingly, the observed histone modification profile of invasive breast cancer cell lines is similar to what is found in individuals who exhibit disease recurrence and have a poor prognosis. These results suggest that metabolically sensitive histone modifications and their corresponding HMEs may be used as diagnostic and prognostic biomarkers. This makes them attractive targets for chemopreventive and chemotherapeutic strategies in breast cancer management. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3021. doi:10.1158/1538-7445.AM2011-3021
Abstract 4723: Soluble L1-CAM in the ascites is a prognostic marker in ovarian cancer
Authors: Sandra Bondong, Thomas Hielscher, Alain Zeimet, Robert Zeillinger, Isabelle Cadron, Jalid Sehouli, Ignace Vergote, Sven Mahner, Paul Speiser, Ioana Braicu, Monica Huszar, Mina Fogel, Peter Altevogt
Journal: Cancer Research (2011)

Abstract L1-cell adhesion molecule (L1-CAM) is a 200-220 kDa transmembrane protein that belongs to the immunoglobulin superfamily. It was initially found to be expressed on neuronal cells and is involved in axon outgrowth and guidance during central nervous system development. L1-CAM overexpression has been reported for various tumor entities, where it correlates with advanced stage disease, metastasis and chemoresistance. In mouse models, L1-CAM promotes tumor growth and facilitates experimental tumor metastasis. The extracellular part of the full length L1-CAM is subject to membrane proximal cleavage, which generates a soluble form of about 200kDa (sL1-CAM). L1-CAM cleavage and release of the soluble molecule has been shown to promote migration, adhesion and protection from apoptosis of ovarian cancer cells in vitro. The soluble L1-CAM can be detected in body fluids like saliva, serum or ascites. In a multi-centric retrospective study with 270 ovarian cancer patients, we analysed tumor samples to quantify membrane bound full length L1-CAM as well as ascites for sL1-CAM to study the value of L1-CAM as a prognostic marker. We found that L1-CAM expression on the tumor correlated with sL1-CAM in the ascites (rho=0.41). Increased L1-CAM levels on the tumor and in the ascites correlated significantly with a reduced overall survival (univariate p=0.028; 0.022). Elevated ascitic L1-CAM levels were also associated with poor progression free survival (p&amp;lt;0.0001) and remained an independent prognostic marker in multivariate analysis (p=0.0003). Furthermore, increased L1-CAM levels in the ascites correlated with an increased ascites volume (p=0.003). Patients with elevated L1-CAM levels in the tumor were at high risk for incomplete primary debulking (univariate p=0.01, multivariate p=0.04) and had an increased risk for lymph node metastases (p=0.004). Given the in vitro role of L1-CAM in metastasis and invasion in addition to the findings of our study, we conclude that L1-CAM high expressing tumors show a more invasive phenotype which translates into a higher rate of incomplete debulking during upfront surgery. High levels of sL1-CAM in the ascites could serve as a reliable marker for prediction of early relapse and residual tumor burden in women suffering from ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4723. doi:10.1158/1538-7445.AM2011-4723
OP0079-HPR Effects of a one week multidisciplinary inpatient self-management programme for patients with fibromyalgia: A randomised controlled trial
Authors: B. Hamnes, I. Kjeken, P. Mowinckel, K.B. Hagen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The European League Against Rheumatism (EULAR)has developed evidence-based recommendations for management of FM. The recommendations are both pharmacological and non-pharmacological. Non-pharmacological recommendations include multidisciplinary approaches, such as self-management programmes (SMP). SMPs have been developed to assist people with chronic rheumatic diseases in their efforts to cope with their disease in daily life. A review of FM studies shows that SMP with or without exercise gave sustained benefits across a range of outcomes for more than 6 months after completion of the SMP. <h3>Objectives</h3> To evaluate effects of a one week multidisciplinary inpatient self-management programme (SMP) on psychological distress, skills as a consumer of health services, self-efficacy, andfunctional and symptomatic consequences of fibromyalgia (FM). <h3>Methods</h3> A randomised controlled two-armed, assessor-blinded trial with three-week follow-up to evaluate SMP. Primary outcomes were the General Health Questionnaire (GHQ-20) and the Effective Musculoskeletal Consumer Scale (EC-17), while secondary outcomes included the Fibromyalgia Impact Questionnaire (FIQ) and Self-efficacy scales for pain, function and symptoms (ASES). <h3>Results</h3> 150 patients with FM were randomised to one week SMP (n=75) or to a waiting list control group (n=75). Of these, 58 participants in the treatment group and 60 in the control group completed the study. At three weeks' follow up there was a significant difference in EC-17 (0-100) in favour of the treatment group (mean difference 4.26, 95% CI 0.8 to 7.7, p=0.02). There were no differences between the groups for any of the other outcomes. <h3>Conclusions</h3> This study shows that in patients with fibromyalgia the SMP has a small short-term effect on skills and behavior that are important for managing and participating in health care (EC-17). <h3>Disclosure of Interest</h3> None Declared